Early Safety Findings Among Persons Aged [greater than or equal to] 60 Years Who Received a Respiratory Syncytial Virus Vaccine--United States, May 3, 2023-April 14, 2024

Authors :: Hause, Anne M.
Moro, Pedro L.
Baggs, James
Zhang, Bicheng
Marquez, Paige
Melgar, Michael
Britton, Amadea
Stroud, Erin
Myers, Tanya R.
Rakickas, Jeffrey
Blanc, Phillip G.
Welsh, Kerry
Broder, Karen R.
Su, John R.
Shay, David K.
Source :: Morbidity and Mortality Weekly Report. May 30, 2024, Vol. 73 Issue 21, p489, 6 p.
Publication Year :: 2024
Abstract: Introduction Respiratory syncytial virus (RSV) infection can cause lower respiratory tract disease, hospitalization, and death in older adults and is responsible for substantial morbidity and mortality among this age group [...]

Subjects :: United States. Food and Drug Administration -- Safety and security measures
Pfizer Inc. -- Safety and security measures
Guillain-Barre syndrome -- Complications and side effects
Vaccination -- Surveys -- Safety and security measures
Respiratory tract diseases -- Complications and side effects
Vaccines -- Complications and side effects
Pharmaceutical industry -- Safety and security measures -- Surveys
Health
Abrysvo (Vaccine) -- Complications and side effects

Tools